Sunday, September 13, 2026

USD/CNH Bearish Momentum With A 1% Slide In The Last 10 Sessions

ViaNews Editorial Team

January 21, 2024

USD/CNH Bearish Momentum With A 1% Slide In The Last 10 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 1.73% for the last 10 sessions. At 14:06 EST on Sunday, 21 January, USD/CNH (USDCNH) is $7.20.

USD/CNH's yearly highs and lows, it's 0% down from its 52-week low and 0% down from its 52-week high.

Previous days news about USD/CNH (USDCNH)

  • Usd/cnh price analysis: edges lower to near 7.2100 followed by support at 23.6% fibonacci. According to FXStreet on Friday, 19 January, "A firm break below the 14-day EMA could put downward pressure on the USD/CNH pair to navigate the support region around the 38.2% Fibonacci retracement level at 7.1772 aligned with the week's low at 7.1748.", "The technical analysis of the Moving Average Convergence Divergence (MACD) for the USD/CNH pair reveals a bullish outlook. "

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Chip Boom Lifts Semiconductors as Export-Control Gaps Persist
AI infrastructure demand is fueling a broad semiconductor rally — Broadcom's AI chip revenue and Q4 guidance, Amazon's custom silicon crossing a $25B annual run rate, and bullish analyst calls on Micron and Sandisk tied to a memory chip boom underestimated even by bulls — with ASML rallying on sympathy. That momentum runs alongside unresolved US-China tech tensions: Belgium's arrest of a suspect for stealing chip technology for China and a blacklisted Chinese firm still acquiring Nvidia's top AI chips show export-control enforcement lagging the pace of AI chip demand.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com